Benzamidine derivatives

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C546S239000, C548S400000, C564S305000, C564S309000

Reexamination Certificate

active

09356492

ABSTRACT:
Benzamidine derivatives of the following formulae or analogs thereof, i.e., pharmaceutically acceptable salts thereof, are provided. These compounds or salts thereof have a blood-coagulation inhibiting effect based on an excellent effect of inhibiting the action of activated blood coagulation factor X, and they are useful as anticoagulants

REFERENCES:
patent: 4018933 (1977-04-01), Schorr et al.
patent: 5518735 (1996-05-01), Stuerzebecher et al.
patent: 6410538 (2002-06-01), Nakagawa et al.
patent: 6710056 (2004-03-01), Sugiki et al.
patent: 6812231 (2004-11-01), Nakagawa et al.
patent: 0 672 658 (1995-09-01), None
patent: 0672658 (1995-09-01), None
patent: 7-330695 (1995-09-01), None
patent: WO 96/28427 (1996-09-01), None
patent: WO 97/24118 (1997-07-01), None
Patani et. al., “Bioisosterism: A Rational Approach in Drug Design”, Chem. Rev. 1996, 96, p. 3170.
R. R. Tidwell, et al., Thrombosis Research 19 , pp. 339-349, “Strategies for Anticoagulation With Synthetic Protease Inhibitors. Xa Inhibitors Versus Thrombin Inhibitors,” 1980.
David J. Robison, et al., The Journal of Biological Chemistry, vol. 255, No. 5, pp. 2014-2021, “Active Site of Bovine Factor Xa,” Mar. 10, 1980.
Takayasu Nagahara, et al., Journal of Medicinal Chemistry, pp. 1200-1207, “Dibasic (Amidinoaryl) Propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors,” 1994.
J.M. Herbert, et al., “DX 9065A, a Novel, Synthetic, Selective and Orally Active Inhibitor of Factor Xa: In Vitro and in Vivo Studies,”The Journal of Pharmacology and Experimental Therapeutics, vol. 276, No. 3, 1996, pp. 1030-1038.
G.P. Vlasuk, et al., “Comparison of the In Vivo Anticoagulant Properties of Standard Heparin and the Highly Selective Factor Xa Inhibitors Antistasin and Tick Anticoagulant Peptide (TAP) in a Rabbit Model of Venous Thrombosis,” Thrombosis and Haemostasis, vol. 65(3), 1991, pp. 257-262.
P.C. Wong, et al. “Antithrombotic Actions of Selective Inhibitors of Blood Coagulation Factor Xa in Rat Models of Thrombosis,” Thrombosis Research, vol. 83, No. 2, 1996, pp. 117-126.
Q. Han, et al., “Design, Synthesis, and Biological Evaluation of Potent and Selective Amidino Bicyclic Factor Xa Inhibitors,” J. Med. Chem., vol. 43, 2000, pp. 4398-4415.
K. Sato, et al., “Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time,” European Journal of Pharmacology, vol. 352, 1998, pp. 59-63.
D.J.P. Pinto, et al., “Discovery of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa1,” J. Med. Chem, vol. 44, 2001, pp. 566-578.
M.R. Wiley, et al., “Structure-Based Design of Potent, Amidine-Derived Inhibitors of Factor Xa: Evaluation of Selectivity, Anticoagulant Activity, and Antithrombotic Activity,” J. Med. Chem., vol. 43, 2000, pp. 883-899.
J. Hirsh, et al., “Guide to Anticoagulant Therapy Part 2: Oral Anticoagulants,” Circulation, vol. 89, No. 3, Mar. 1994, pp. 1469-1480.
J. Hirsh, et al., “Guide to Anticoagulant Therapy Part 1: Heparin,” Circulation, vol. 89, No. 3, Mar. 1994, pp. 1449-1468.
B. Kaiser, “Factor Xa Versus Factor IIa Inibitors,” Clin. Appl. Thrombosis/Hemostasis, vol. 3(1), 1997, pp. 16-24.
B. Tatlisumak, et al., “Hematologic disorders associated with ischemic stroke,” Journal of Neurological Sciences, vol. 140, 1996, pp. 1-11.
H. Kawai, et al., “Effects of a Thrombin Inhibitor, Argatroban, on Ischemic Brain Damage in the Rat Distal Middle Cerebral Artery Occlusion Model,” The Journal of Pharmacology and Experimental Therapeutics, vol. 278, No. 2, 1996, pp. 780-785.
F.A. Spencer, et al., “Novel Inhibitors of Factor X for Use in Cardiovascular Diseases,” Current Cardiology Reports, vol. 2, 2000, pp. 395-404.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Benzamidine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzamidine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzamidine derivatives will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3958844

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.